SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-313909
Filing Date
2020-12-09
Accepted
2020-12-09 17:08:54
Documents
16
Period of Report
2020-12-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d47039d8k.htm   iXBRL 8-K 28701
2 EX-1.1 d47039dex11.htm EX-1.1 240017
3 EX-4.1 d47039dex41.htm EX-4.1 63482
4 EX-5.1 d47039dex51.htm EX-5.1 12675
8 GRAPHIC g47039dsp60.jpg GRAPHIC 2588
  Complete submission text file 0001193125-20-313909.txt   562023

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA atra-20201208.xsd EX-101.SCH 3070
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE atra-20201208_lab.xml EX-101.LAB 18139
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atra-20201208_pre.xml EX-101.PRE 11408
9 EXTRACTED XBRL INSTANCE DOCUMENT d47039d8k_htm.xml XML 3440
Mailing Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Business Address 611 GATEWAY BLVD SUITE 900 SOUTH SAN FRANCISCO CA 94080 650-278-8930
Atara Biotherapeutics, Inc. (Filer) CIK: 0001604464 (see all company filings)

IRS No.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36548 | Film No.: 201378518
SIC: 2836 Biological Products, (No Diagnostic Substances)